Share on StockTwits

Akebia Therapeutics (NASDAQ:AKBA) posted its quarterly earnings results on Monday. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.34) by $0.05, Analyst Ratings.Net reports.

Akebia Therapeutics (NASDAQ:AKBA) traded up 4.20% on Monday, hitting $22.60. 95,434 shares of the company’s stock traded hands. Akebia Therapeutics has a 1-year low of $16.41 and a 1-year high of $31.00. The stock has a 50-day moving average of $24.39 and a 200-day moving average of $23.6. The company’s market cap is $413.6 million. Akebia Therapeutics also was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 973,463 shares, a drop of 21.7% from the July 15th total of 1,242,775 shares. Based on an average daily trading volume, of 121,193 shares, the short-interest ratio is presently 8.0 days. Approximately 11.2% of the company’s stock are short sold.

Akebia Therapeutics Inc is a United States-based biopharmaceutical company, which is focused on the development of small molecules for the treatment of anemia and vascular disease.

Receive News & Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.